This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Briefing complete in Teva US appellate bid to maintain stay of Orange Book injunction

By Melissa Ritti ( January 14, 2025, 17:20 GMT | Insight) -- In a redacted reply brief filed yesterday, Teva Pharmaceuticals USA reiterated its entitlement to a stay on the enforcement of a New Jersey federal judge’s injunction which directed Teva to remove five patents from the Orange Book of Approved Drugs. The Israeli drugmaker is hoping to stop the delisting while its forthcoming petition for panel rehearing or rehearing en banc is considered by the US Court of Appeals for the Federal Circuit.Amneal Pharmaceuticals stands to lose nothing if five inhaler patents remain listed in the US Food and Drug Administration’s Orange Book of Approved Drugs, while Teva Pharmaceuticals USA will suffer “certain, irreparable harm,” Teva argued yesterday....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections